Abstract Number: 2535 • ACR Convergence 2024
The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation
Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…Abstract Number: 0099 • ACR Convergence 2024
Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play important roles in antiphospholipid syndrome (APS) pathogenesis. To kill microbes and propel…Abstract Number: 0115 • ACR Convergence 2024
Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry
Background/Purpose: The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune rheumatic diseases…Abstract Number: 0639 • ACR Convergence 2024
Delayed Diagnosis in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…Abstract Number: 0100 • ACR Convergence 2023
The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients
Background/Purpose: The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti β2-glycoprotein-I (aβ2GPI) antibodies, is ill-defined in the pediatric…Abstract Number: 0116 • ACR Convergence 2023
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state, leading to arterial, venous, or microvascular thrombosis and accelerated atherosclerosis. Timely diagnosis…Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…Abstract Number: 0579 • ACR Convergence 2023
Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes
Background/Purpose: Ischemic stroke is 2-3 times more common in patients with SLE as compared to the general population, and genetic susceptibility in the STAT4 and…Abstract Number: 0102 • ACR Convergence 2023
The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome Patients
Background/Purpose: Acute myocardial infarction (AMI) can be divided into coronary artery disease (MICAD) or nonobstructive coronary arteries (MINOCA) according to the severity of artery stenosis…Abstract Number: 0738 • ACR Convergence 2023
A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is a rare autoimmune disease characterized by the presence of antiphospholipid antibodies and the occurrence of thrombotic events and pregnancy…Abstract Number: 0103 • ACR Convergence 2023
Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study
Background/Purpose: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. Late pregnancy morbidity occurs in up to 25% of pregnant women with APS and may…Abstract Number: 0912 • ACR Convergence 2023
Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid Syndrome (APS) is classified into primary and secondary; the latter being associated with connective tissue disease. Systemic lupus erythematosus (SLE) is the most…Abstract Number: 0104 • ACR Convergence 2023
Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study
Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…Abstract Number: 1208 • ACR Convergence 2023
Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study
Background/Purpose: Substantial morbidity and mortality affect those with aPLs and APS, yet the patient experience remains poorly understood. This research investigated patient experiences of aPL/APS…Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 19
- Next Page »